# EMBP (1.B.787): sc-59163



The Power to Question

# **BACKGROUND**

The eosinophil major basic protein (EMBP), also designated MBP, PRG2, proteoglycan 2, BMPG or bone marrow natural killer cell activator, is a constituent of the crystalline core of the eosinophil granule. High levels of the pro-EMBP are present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT) and C3dg. EMBP may influence antiparasitic defense mechanisms as a cytotoxin and helminthotoxin, and in immune hypersensitivity reactions. It stimulates an Src kinase-dependent activation of class I(A) phosphoinositide 3-kinase and, in turn, activation of protein kinase  $C\zeta$  in neutrophils. EMBP transcription is under regulation by novel combinatorial interactions of GATA-1, PU.1, and C/EBP $\epsilon$  isoforms.

# **REFERENCES**

- Oxvig, C., et al. 1993. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J. Biol. Chem. 268: 12243-12246.
- Popken-Harris, P. et al. 1995. Expression, purification, and characterization of the recombinant proform of eosinophil granule major basic protein. J. Immunol. 155: 1472-1480.
- Larson, K.A., et al. 1995. The identification and cloning of a murine major basic protein gene expressed in eosinophils. J. Immunol. 155: 3002-3012.
- 4. Li, M.S., et al. 1995. Human eosinophil major basic protein, a mediator of allergic inflammation, is expressed by alternative splicing from two promoters. Biochem. J. 305: 921-927.
- 5. Mujtaba, M.G., et al. 1997. CD4 T suppressor cells mediate interferon  $\tau$  protection against experimental allergic encephalomyelitis. J. Neuro-immunol. 75: 35-42.
- Mukai, H.Y., et al. 1997. Elevated serum levels of eosinophil major basic protein in patients with myeloproliferative disorders without eosinophilia. Int. J. Hematol. 66: 197-202.
- Yamaguchi, Y., et al. 1999. C/EBPβ and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: implication for C/EBPβ activity in eosinophil gene expression. Blood 94: 1429-1439.
- Overgaard, M.T., et al. 2000. Expression of recombinant human pregnancyassociated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J. Biol. Chem. 275: 31128-31133.
- 9. Swaminathan, G.J., et al. 2001. Crystal structure of the eosinophil major basic protein at 1.8 A. An atypical lectin with a paradigm shift in specificity. J. Biol. Chem. 276: 26197-203.

# CHROMOSOMAL LOCATION

Genetic locus: PRG2 (human) mapping to 11q12.1.

#### **SOURCE**

EMBP (1.B.787) is a mouse monoclonal antibody raised against full length EMBP of human origin.

#### **PRODUCT**

Each vial contains 100  $\mu g\ lgG_1$  in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

# **APPLICATIONS**

EMBP (1.B.787) is recommended for detection of EMBP irrespective of the stages of eosinophil activation of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500); also recommended for detection of secreted pro-form of MBP (Pregnancy associated MBP, 23.8kDa) and mature form found in the matrix of the eosinophil large specific granule (13.8kDa).

Suitable for use as control antibody for EMBP siRNA (h): sc-44577, EMBP shRNA Plasmid (h): sc-44577-SH and EMBP shRNA (h) Lentiviral Particles: sc-44577-V.

Molecular Weight of proEMBP precursor: 25 kDa.

Molecular Weight of mature EMBP: 14 kDa.

Positive Controls: MEG-01 cell lysate: sc-2283.

### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

# **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com